Side effects of lower dose compounded semaglutide paired with a behavioral management program: A real-world retrospective study

What was studied

Whether a lower-dose compounded semaglutide program was associated with fewer reported side effects than a higher-dose program during the first 16 weeks.

Who / model studied

A retrospective real-world cohort of program users. The primary matched analysis included 2,481 users per group, and a second matched analysis included 958 per group.

Studied dose & schedule

In this retrospective, matched comparison over the first 16 weeks, users of compounded semaglutide in the lower-dose program received up to 0.6 mg weekly, while those in the standard-dose program received up to 1.2 mg weekly. The supplied abstract does not specify administration route, starting dose, or individual schedules; these are program ceilings, not equivalent doses received by every participant.

What the study found

By week 16, the lower-dose program was associated with 34% lower odds of reported gastrointestinal side effects and 29% lower odds of any reported side effect. The second matched analysis also favored the lower-dose program.

Limitations & context

This was retrospective and compared two compounded-drug programs paired with behavioral support. Association does not prove that dose alone caused the difference, and the abstract does not report weight-loss outcomes.

Read summary source ↗ · Prepared 9/15/2026 · AI-assisted, source-based summary